Discontinued — last reported Q2 '20

Current Liabilities

Lease Liability - Undiscounted Excess Amount

International Business Machines Lease Liability - Undiscounted Excess Amount increased by 39.2% to $479.00M in Q4 2025 compared to the prior quarter. Over 2 years (FY 2023 to FY 2025), Lease Liability - Undiscounted Excess Amount shows an upward trend with a 5.7% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.

Analysis

StatementBalance Sheet Statement
SectionCurrent Liabilities
CategoryLiquidity
SignalLower is better
VolatilityStable
First reportedQ4 2019
Last reportedQ2 2020

How to read this metric

An increase indicates a larger total contractual burden, which may constrain future cash flow flexibility.

Detailed definition

This is the aggregate undiscounted amount of all future lease payments, including both operating and finance leases, tha...

Peer comparison

Used by analysts to normalize lease obligations across companies with varying discount rates and lease terms.

Metric ID: lease_liability_undiscounted_excess

Historical Data

3 periods
 Q4 '23Q4 '24Q4 '25
Value$429.00M$344.00M$479.00M
QoQ Change-19.8%+39.2%
YoY Change-19.8%+39.2%
Range$344.00M$479.00M
Avg YoY Growth+9.7%
Median YoY Growth+9.7%

Frequently Asked Questions

What is International Business Machines's lease liability - undiscounted excess amount?
International Business Machines (IBM) reported lease liability - undiscounted excess amount of $479.00M in Q4 2025.
What is the long-term trend for International Business Machines's lease liability - undiscounted excess amount?
Over 2 years (2023 to 2025), International Business Machines's lease liability - undiscounted excess amount has grown at a 5.7% compound annual growth rate (CAGR), from $429.00M to $479.00M.
What does lease liability - undiscounted excess amount mean?
The total nominal value of all future lease payments before discounting to present value.

Cookie Preferences

We use cookies for analytics. See our Privacy and Cookie Policy.